The FKBPL-based therapeutic peptide, AD-01, protects the endothelium from hypoxia-induced damage by stabilising hypoxia inducible factor-α and inflammation
FKBPL represents an important novel mechanism in hypoxia and inflammation-induced angiogenesis. The FKBPL-based therapeutic peptide, AD-01, could be a viable treatment option for CVD-related endothelial cell dysfunction.
Authors
- Mary Meltem Kavurma (ORCID: https://orcid.org/0000-0001-7353-0932)
- Lana McClements (ORCID: https://orcid.org/0000-0002-4911-1014)
- Matthew Paul Padula (ORCID: https://orcid.org/0000-0002-8283-0643)
- Siân P. Cartland (ORCID: https://orcid.org/0000-0003-1723-2679)
- Rupert Ecker (ORCID: https://orcid.org/0000-0002-1095-8592)
- Claire Richards (ORCID: https://orcid.org/0000-0001-5080-9164)
- Majid Ebrahimi Warkiani (ORCID: https://orcid.org/0000-0002-4184-1944)
- Dunja Aksentijević (ORCID: https://orcid.org/0000-0002-8480-6727)
- Louise Cole (ORCID: https://orcid.org/0000-0001-9206-9272)
- Hao Chen (ORCID: https://orcid.org/0000-0001-8319-8101)
- Sahar Ghorbanpour (ORCID: https://orcid.org/0000-0001-5614-5215)
- Sanchit Seth
Institutions
- University of Technology Sydney (AU)
- The University of Sydney (AU)
- Translational Research Institute (AU)
- Queensland University of Technology (AU)
- Queen Mary University of London (GB)
- The Heart Research Institute (AU)
- William Harvey Research Institute (GB)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1186/s12967-025-06118-w
- Citations
- 6
- Primary Topic
- Signaling Pathways in Disease
- Type
- article
- Field-Weighted Citation Impact
- 4.84
Funders
- National Heart Foundation of Australia